10 Easy Double-Digit Gainers

8. Roivant Sciences Ltd. (NASDAQ:ROIV)

Roivant saw its share prices jump by 19.4 percent week-on-week, hitting a new all-time high, as investors snapped up shares following encouraging results from its pipeline projects, with one already seeking a new drug application (NDA) approval.

In Friday’s trading, the stock jumped to its highest price of $25.95 before trimming a few cents to finish the day just up by 22.14 percent at $25.82 apiece.

In an updated report, Roivant Sciences Ltd. (NASDAQ:ROIV) said that its unit, Priovant, saw strong results from its clinical trial of Brepocitinib in patients with cutaneous sarcoidosis (CS), having achieved a 22.3 percent improvement in CSAMI-A score—a measure of cutaneous sarcoidosis disease activity—after a 16-week therapy. This compares with a 0.7 percent improvement in the placebo group.

Meanwhile, Priovant has submitted an NDA with the Food and Drug Administration for the approval of brepocitinib to treat dermatomyositis.

A third clinical trial to check the efficacy of the therapy candidate for patients with non-infectious uveitis (NIU) is expected in the second half of calendar year 2026.

Meanwhile, Roivant Sciences Ltd. (NASDAQ:ROIV), through its other business units Immunovant and Pulmovant are underway with the clinical trials of other therapy candidates for the treatment of difficult-to-treat rheumatoid arthritis, Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropath, Sjögren’s disease, and cutaneous lupus erythematosus, as well as pulmonary hypertension.

On Friday, Roivant Sciences Ltd. (NASDAQ:ROIV) also reported dismal earnings performance for the third quarter ending December 31, with the company swinging to a net loss attributable to shareholders of $265.89 million versus a $169 million attributable net income in the same period a year earlier.

The figure brought its attributable net loss in the nine-month period to $602.76 million, versus a $34.49 million attributable net income in the same period a year earlier.